Literature DB >> 1970444

The phorbol ester TPA strongly inhibits HIV-1-induced syncytia formation but enhances virus production: possible involvement of protein kinase C pathway.

I H Chowdhury1, Y Koyanagi, S Kobayashi, Y Hamamoto, H Yoshiyama, T Yoshida, N Yamamoto.   

Abstract

Cocultivation of MOLT-4 and MOLT-4/HIVHTLV-IIIB cells with more than 0.01 ng/ml of 12-O-tetradecanoylphorbol-13-acetate (TPA) for 20 hr strikingly inhibited HIV-induced syncytia formation resulting from cell to cell infection. Interestingly, the production of HIV-specific p24 antigen in the culture fluid was significantly enhanced by TPA. TPA down-modulated the expression of CD4. CD4 is essential for syncytia formation through interaction with viral envelope protein gp120 on the surface of MOLT-4 cells. The effects of TPA on syncytia formation and on CD4 expression were specifically interfered with by nontoxic doses of blockers of protein kinase C (PKC) such as staurosporine and H7. These data suggest that (1) TPA inhibits HIV-induced syncytia formation through down-modulation of CD4 molecules on the surface of MOLT-4 cells and (2) PKC may play an important role in cell to cell as well as in cell-free infection of HIV.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1970444     DOI: 10.1016/0042-6822(90)90237-l

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  14 in total

1.  A duodenally absorbable CXC chemokine receptor 4 antagonist, KRH-1636, exhibits a potent and selective anti-HIV-1 activity.

Authors:  Kozi Ichiyama; Sei Yokoyama-Kumakura; Yuetsu Tanaka; Reiko Tanaka; Kunitaka Hirose; Kenji Bannai; Takeo Edamatsu; Mikiro Yanaka; Yoshiaki Niitani; Naoko Miyano-Kurosaki; Hiroshi Takaku; Yoshio Koyanagi; Naoki Yamamoto
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-17       Impact factor: 11.205

2.  Human T-cell leukemia virus type-I (HTLV-I) tax is not the only one factor to enhance human immunodeficiency virus type-I (HIV-1) infection in culture-supernatants.

Authors:  A Tempaku; Y Maeda; W Song; S Harada
Journal:  Virus Genes       Date:  2001       Impact factor: 2.332

3.  Mechanism of selective inhibition of human immunodeficiency virus by ingenol triacetate.

Authors:  M Fujiwara; K Ijichi; K Tokuhisa; K Katsuura; S Shigeta; K Konno; G Y Wang; D Uemura; T Yokota; M Baba
Journal:  Antimicrob Agents Chemother       Date:  1996-01       Impact factor: 5.191

4.  Human T-cell lymphotropic virus type 1 Tax1 activation of NF-kappa B: involvement of the protein kinase C pathway.

Authors:  P F Lindholm; M Tamami; J Makowski; J N Brady
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

5.  Evaluation of anti-human immunodeficiency virus effect of recombinant CD4-immunoglobulin in vitro: a good candidate for AIDS treatment.

Authors:  I H Chowdhury; Y Koyanagi; K Takamatsu; O Yoshida; S Kobayashi; N Yamamoto
Journal:  Med Microbiol Immunol       Date:  1991       Impact factor: 3.402

6.  Stimulation of virus production and induction of self-syncytium formation in human T-cell leukemia virus type I- and type II-infected T cells by 12-O-tetradecanoylphorbol-13-acetate.

Authors:  M Wolfson; M Lev; I Avinoah; Z Malik; M Löchelt; R M Flügel; A Dombrovski; M Aboud
Journal:  J Virol       Date:  1994-07       Impact factor: 5.103

7.  Increased production of human immunodeficiency virus (HIV) in HIV-induced syncytia formation: an efficient infection process.

Authors:  M I Chowdhury; Y Koyanagi; M Suzuki; S Kobayashi; K Yamaguchi; N Yamamoto
Journal:  Virus Genes       Date:  1992-01       Impact factor: 2.332

8.  Identification of membrane antigen C33 recognized by monoclonal antibodies inhibitory to human T-cell leukemia virus type 1 (HTLV-1)-induced syncytium formation: altered glycosylation of C33 antigen in HTLV-1-positive T cells.

Authors:  K Fukudome; M Furuse; T Imai; M Nishimura; S Takagi; Y Hinuma; O Yoshie
Journal:  J Virol       Date:  1992-03       Impact factor: 5.103

9.  Inhibition of protein kinase C results in decreased expression of bovine leukemia virus.

Authors:  W A Jensen; B J Wicks-Beard; G L Cockerell
Journal:  J Virol       Date:  1992-07       Impact factor: 5.103

10.  The phorbol ester phorbol myristate acetate inhibits human immunodeficiency virus type 1 envelope-mediated fusion by modulating an accessory component(s) in CD4-expressing cells.

Authors:  H Golding; J Manischewitz; L Vujcic; R Blumenthal; D S Dimitrov
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.